Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort is a logistics company that is making significant strides in the life sciences industry, with strong revenue growth and new facilities in its Life Sciences Services division. Its upcoming launch in Paris is expected to further contribute to its growth. With a promising outlook for the future and a growing portfolio of commercial therapies, CryoPort is well-positioned to take advantage of the rapidly expanding cell and gene therapy market. Additionally, the company's successful second quarter was driven by positive momentum in key areas, such as the expansion of its BioLogistics services and growth in commercial therapy volumes. With positive EBITDA and revenue growth and a specialized equipment strategy, CryoPort presents a promising investment opportunity that aligns with the growing trends of cell and gene therapy commercialization and globalization of supply chains.

Bears say

CryoPort is facing slowing growth in its Life Sciences Products segment, which generates around 45% of its revenue, and is heavily reliant on its MVE Biological Solutions division. Despite its upcoming CryoVerse Ecosystem and the deployment of AI, these initiatives may not immediately reflect in financials and labor intensiveness could impede operating leverage. Even with potential upside drivers, the company will continue to face challenges in scaling its service platform without proportionate headcount additions.

CryoPort (CYRX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, CryoPort (CYRX) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.